Asadirad, 60 patient curcumin late treatment RCT: 26% lower mortality [p=0.74], 50% lower progression [p=0.47], and 45% improved recovery [p=0.09] https://c19p.org/asadirad
copied to clipboard
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial
et al., Phytotherapy Research, doi:10.1002/ptr.7375
RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days.
|
risk of death, 25.9% lower, RR 0.74, p = 0.74, treatment 5 of 27 (18.5%), control 6 of 24 (25.0%), NNT 15, excluding patients that stopped treatment due to progression - 3 for curcumin and 6 for control.
|
|
risk of progression, 50.0% lower, RR 0.50, p = 0.47, treatment 3 of 30 (10.0%), control 6 of 30 (20.0%), NNT 10.0.
|
|
risk of unresolved fever, 45.3% lower, RR 0.55, p = 0.09, treatment 8 of 27 (29.6%), control 13 of 24 (54.2%), NNT 4.1.
|
|
risk of unresolved dyspnea, 28.9% lower, RR 0.71, p = 0.72, treatment 4 of 27 (14.8%), control 5 of 24 (20.8%), NNT 17.
|
|
risk of unresolved cough, 40.7% lower, RR 0.59, p = 0.36, treatment 6 of 27 (22.2%), control 9 of 24 (37.5%), NNT 6.5.
|
|
risk of O2 <92%, 36.5% lower, RR 0.63, p = 0.51, treatment 5 of 27 (18.5%), control 7 of 24 (29.2%), NNT 9.4.
|
|
risk of O2 <97%, 20.0% lower, RR 0.80, p = 0.21, treatment 18 of 27 (66.7%), control 20 of 24 (83.3%), NNT 6.0.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Asadirad et al., 1/17/2022, Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, 7 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.